Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aardvark Therapeutics

Request full access

The development and commercialization of safe and effective small molecule therapeutics that have broad therapeutic potential

San Diego, United StatesFounded 2017Biotech & Life Sciences

About Aardvark Therapeutics

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of safe and effective small molecule therapeutics. The company's lead product, ARD 101, is an oral drug designed to have low systemic exposure while activating gut peptide hormone secretion and gut-brain signaling. This innovative approach aims to treat a variety of metabolic and inflammatory diseases. Aardvark Therapeutics operates in the biopharmaceutical market, primarily serving patients with complex medical conditions that require advanced therapeutic solutions. The company generates revenue through the development and eventual commercialization of its drug candidates, with a focus on achieving regulatory approval and market entry. Chief Medical Officer Dr. Andreas Niethammer, who has extensive experience in translational medicine and executive roles at major pharmaceutical companies, leads the clinical development efforts. Key aspects of Aardvark's business model include leveraging preclinical and clinical data to support the efficacy and safety of its drug candidates, and focusing on the therapeutic potential of bitter taste receptors (Tas2Rs), which are expressed on many cells throughout the body. The company aims to address unmet medical needs by providing novel treatments that offer broad therapeutic potential.

Source: Dealroom company data

At a glance

Status
Operational
Employees
34
Open positions
None listed
Dealroom signal
50.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPOOther financing Feb 2025 $94M $94M Undisclosed ↗
SERIES COther financing May 2024 $85M $340M Vickers Venture Partners · Cantor Fitzgerald · LG Technology Ventures · Foundation for Prader-Willi Syndrome Research ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026 — —
2025 — —
2024 — —
2023 — —
2022 — —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Aardvark Therapeutics website traffic

Latest recorded traffic for Aardvark Therapeutics is 6.3K monthly website visits, up 34% over the last three months. Aardvark Therapeutics's team grew 126.7% over the past year.

Latest monthly visits6.3K 3-month web change+34% 1-year team growth+126.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Aardvark Therapeutics in the San Diego ecosystem

Live from Dealroom

The Aardvark Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

17 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Vickers Venture Partners
  • BNH Investment
  • Premier Partners
  • Korea Omega Investment
  • Sorrento Therapeutics
  • Foundation for Prader-Willi Syndrome Research

Series B and later11 investors entered at this stage

  • Decheng Capital
  • Cantor Fitzgerald
  • LG Technology Ventures
  • Walleye Capital
  • Surveyor Capital
  • SymBiosis
  • Prader-Willi Syndrome Association USA
  • Cormorant Asset Management
  • Tetragon Financial Group
  • Laurion Capital Management
  • Silver Arch Capital Partners
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States96.5%
🇧🇷 Brazil3.5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aardvark Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aardvark Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.